Press Releases

Media Focus

QbD for biopharmaceutical product lifecycle management


Establishing an end-to-end drug life cycle that builds on Quality-by-Design (QbD) principles is important for CDMOs to develop and manufacture quality products. 


Two of our QbD experts – Youngsun Kim and Busol Park – share key considerations for developing a QbD-led CDMO strategy that spans process characterization to commercial manufacturing. 


Read More


Establishing an end-to-end drug life cycle that builds on Quality-by-Design (QbD) principles is important for CDMOs to develop and manufacture quality products. 


Two of our QbD experts – Youngsun Kim and Busol Park – share key considerations for developing a QbD-led CDMO strategy that spans process characterization to commercial manufacturing. 


Read More

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION